Method And Substance For The Treatment Of Cerebral Amyloid Angiopathy

Tech ID: 29888 / UC Case 2016-470-0


UCLA researchers in the Department of Pathology have identified a novel pathway that causes β-amyloid-associated smooth muscle cell loss in Cerebral Amyloid Angiopathy (CAA) cases.


Cerebral amyloid angiopathy (CAA) is a pathologic condition characterized by amyloid deposits in the blood vessels that causes loss of smooth muscle cells. It is associated with several diseases, with nearly 70-90% prevalence in Alzheimer’s disease (AD) cases and even some cases of prion diseases. Currently, it is untreatable as most AD therapeutics modulate the immune system often exacerbating the underlying CAA pathology. The lack of effective therapeutics is due to a lack of understanding of the toxic pathway that causes cell loss.


UCLA researchers have identified a novel pathway for therapeutic intervention in CAA-associated neurological disorders. They have identified the different components involved specifically in CAA pathology. The pathway discovered involves several proteins of the immune response. One or more of these components can be targeted for therapeutic intervention.


  • Treatment of CAA-associated Alzheimer’s disease
  • Treatment of Cerebral Hemorrhage


  • Mechanism conserved in all CAA-associated cases
  • Therapeutic targets are small proteins

State Of Development

  • Tested extensively in human autopsy material
  • Validated by multiple biochemical approaches

Patent Status

Country Type Number Dated Case
United States Of America Published Application 20150297674 10/22/2015 2016-470

Related Materials


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Vinters, Harry V.

Other Information


Amyloid, Amyloid-beta, Cerebral Amyloid Angiopathy, Alzheimer’s disease, Prion disease, Neuroinflammation

Categorized As